Aim:Patients with chronic liver disease(CLD),especially cirrhosis,are at a high risk of severe illness or death from coronavirus disease-2019(COVID-19)and may have a suboptimal immune response to the severe acute resp...Aim:Patients with chronic liver disease(CLD),especially cirrhosis,are at a high risk of severe illness or death from coronavirus disease-2019(COVID-19)and may have a suboptimal immune response to the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)vaccine.This study aimed to evaluate the safety and immunogenicity of the COVID-19 booster vaccination in patients with CLD.Methods:The study protocol was prospectively registered at ClinicalTrials.gov(No.NCT05204602)after approval by the Ethics Committee.Adult participants with CLD were enrolled in this multicenter prospective study.They completed two doses of the inactivated COVID-19 vaccine and received booster doses at least 6 months later.Adverse reactions were recorded within 14 days after the booster dose.Serum samples of the enrolled patients were collected before and after booster vaccination and tested for SARS-CoV-2 receptor-binding domain(RBD)immunoglobulin G and neutralizing anti-bodies.The chi-squared or Fisher's exact test was used to compare categorical data,and the Mann-Whitney U test was used to compare continuous variables.Two-sided p<0.05 were considered statistically significant.Results:In total,63 patients were enrolled from four hospitals in China,including 29 patients with cirrhosis.The median age of all patients was 55 years,and 61.9%(39/63)were male.The vaccines were well tolerated;most adverse reactions were mild and transient,and injection site pain(6.4%;4/63)and fatigue(3.2%,2/63)were the most frequent local and systemic adverse events.Following the booster vaccination,our results showed that in the whole cohort,the levels and positive rates of anti-RBD IgG and neutralizing antibodies were significantly higher than baseline levels(all p<0.05).Conclusions:The inactivated COVID-19 booster vaccine was safe and significantly increased antibody levels and positivity rates following standard vaccination regimens in patients with CLD,especially those with cirrhosis.展开更多
Anisotropy and inhomogeneity are ubiquitous in spark plasma sintered thermoelectric devices.However,the origin of inhomogeneity in thermoelectric nanocomposites has rarely been investigated so far.Herein,we systematic...Anisotropy and inhomogeneity are ubiquitous in spark plasma sintered thermoelectric devices.However,the origin of inhomogeneity in thermoelectric nanocomposites has rarely been investigated so far.Herein,we systematically study the impact of inhomogeneity in spark plasma sintered bismuth antimony telluride(BiSbTe)thermoelectric nanocomposites fabricated from solution-synthesized nanoplates.The figure of merit can reach 1.18,which,however,can be overestimated to 1.88 without considering the inhomogeneity.Our study reveals that the inhomogeneity in thermoelectric properties is attributed to the non-uniformity of porosity,textures and elemental distribution from electron backscatter diffraction and energy-dispersive spectroscopy characterizations.This finding suggests that the optimization of bulk material homogeneity should also be actively pursued in any future thermoelectric material research.展开更多
基金prospectively registered at ClinicalTrials.gov (NCT05204602)after approval by the ethics committee (The Third Central Hospital of Tianjin,No.IRB2021-026-01Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine,No.KY2021133+1 种基金Jincheng People's Hospital,No.20210603Lishui People's Hospital,No.2021[007-01]).
文摘Aim:Patients with chronic liver disease(CLD),especially cirrhosis,are at a high risk of severe illness or death from coronavirus disease-2019(COVID-19)and may have a suboptimal immune response to the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)vaccine.This study aimed to evaluate the safety and immunogenicity of the COVID-19 booster vaccination in patients with CLD.Methods:The study protocol was prospectively registered at ClinicalTrials.gov(No.NCT05204602)after approval by the Ethics Committee.Adult participants with CLD were enrolled in this multicenter prospective study.They completed two doses of the inactivated COVID-19 vaccine and received booster doses at least 6 months later.Adverse reactions were recorded within 14 days after the booster dose.Serum samples of the enrolled patients were collected before and after booster vaccination and tested for SARS-CoV-2 receptor-binding domain(RBD)immunoglobulin G and neutralizing anti-bodies.The chi-squared or Fisher's exact test was used to compare categorical data,and the Mann-Whitney U test was used to compare continuous variables.Two-sided p<0.05 were considered statistically significant.Results:In total,63 patients were enrolled from four hospitals in China,including 29 patients with cirrhosis.The median age of all patients was 55 years,and 61.9%(39/63)were male.The vaccines were well tolerated;most adverse reactions were mild and transient,and injection site pain(6.4%;4/63)and fatigue(3.2%,2/63)were the most frequent local and systemic adverse events.Following the booster vaccination,our results showed that in the whole cohort,the levels and positive rates of anti-RBD IgG and neutralizing antibodies were significantly higher than baseline levels(all p<0.05).Conclusions:The inactivated COVID-19 booster vaccine was safe and significantly increased antibody levels and positivity rates following standard vaccination regimens in patients with CLD,especially those with cirrhosis.
基金R.K.C.acknowledges grant#NSF(DMR-1508420).Y.W.thanks the support from the Herbert L.Stiles Professorship and ACRI Center IrHtiative from Iowa State University.
文摘Anisotropy and inhomogeneity are ubiquitous in spark plasma sintered thermoelectric devices.However,the origin of inhomogeneity in thermoelectric nanocomposites has rarely been investigated so far.Herein,we systematically study the impact of inhomogeneity in spark plasma sintered bismuth antimony telluride(BiSbTe)thermoelectric nanocomposites fabricated from solution-synthesized nanoplates.The figure of merit can reach 1.18,which,however,can be overestimated to 1.88 without considering the inhomogeneity.Our study reveals that the inhomogeneity in thermoelectric properties is attributed to the non-uniformity of porosity,textures and elemental distribution from electron backscatter diffraction and energy-dispersive spectroscopy characterizations.This finding suggests that the optimization of bulk material homogeneity should also be actively pursued in any future thermoelectric material research.